Piramal Pharma Q1 FY27: Standalone PAT flat at Rs 113 Cr, Consolidated loss Rs 69 Cr

Net loss reportedEBITDA margin compressionResults View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹195.20

prior close

₹194.99

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.7%+1.5% vs market

Pharmaceuticals peers, median of 162sector-0.8%+1.6% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Smallcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.8

10m

+1.3

15m

+1.0

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8-0.7+1.5-0.8+1.6

Next day

-0.2-0.3+0.1-0.5+0.3

+2.3+1.0+1.3+0.2+2.2

+3.4+1.2+2.2+0.1+3.3

+5.0+1.9+3.1+0.5+4.5

+6.5+2.1+4.4+0.4+6.1

+9.8+2.0+7.7+1.4+8.4

15d

+11.0+2.0+9.0+0.3+10.7

+10.2+2.2+8.0+1.6+8.6

+5.5-1.0+6.5+2.7+2.9

+21.8pendingpending-3.1+24.9

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma Q1 FY27 standalone revenue rose 16% YoY to Rs 1,125 Cr, with PAT flat at Rs 113.48 Cr versus Rs 113.14 Cr. EPS stood at Rs 0.85. Consolidated revenue grew 17% to Rs 2,270 Cr, but the company posted a net loss of Rs 69.39 Cr versus a Rs 81.70 Cr loss. No exceptional items this quarter. Standalone EBITDA margin compressed. Limited review by auditors was clean.

Likely market impact

Mixed quarter: good revenue growth, but standalone margins compressed and consolidated remained in losses. Margin trends are the key watch.